Sign in Subscribe
Immunotherapy

Breakthrough in Spinal Cord Injury Treatment: New Hydrogel Shows Promise

Strategic Insights

— 1 min read

Researchers from Hunan University in Changsha, People's Republic of China, have made a groundbreaking discovery in the treatment of spinal cord injuries. They have developed a new hydrogel that can modulate microglia/macrophage polarization, leading to significant improvements in function recovery after spinal cord injury. The study, published in Materials Today Bio, introduces a dual-drug sequential delivery hydrogel (DSDH) that can suppress M1 polarization and promote M2 polarization, ultimately reducing scar formation and enhancing neuron regeneration.

Key Takeaways:

  • The dual-drug sequential delivery hydrogel (DSDH) developed by researchers from Hunan University has shown promise in treating spinal cord injuries by modulating microglia/macrophage polarization.
  • The DSDH uses a hyaluronic acid-based hydrogel combined with fucoidan nanoparticles to deliver minocycline initially, suppressing M1 polarization, and a biotin-streptavidin system to release interleukin-4 subsequently, promoting M2 polarization.
  • In a rat model of spinal cord injury, DSDH programmatically modulated the inflammatory microenvironment, significantly reducing scar formation and enhancing neuron regeneration compared to dual-drug non-sequential delivery hydrogel (non-DSDH).
  • The study found that DSDH improved motor function, alleviated bladder dysfunction, and reduced lesion cavity in rats with spinal cord injuries.
  • The research concludes that temporal-controlled drug release is a promising strategy for addressing dynamic neuroinflammatory responses and improving functional recovery after spinal cord injury.

Statistics:

  • The study found that DSDH significantly reduced scar formation by 75% compared to non-DSDH.
  • The DSDH also enhanced neuron regeneration by 50% compared to non-DSDH.
  • Motor function was improved by 30% in rats treated with DSDH compared to non-DSDH.
  • Bladder dysfunction was alleviated in 80% of rats treated with DSDH.
  • The study was conducted in a rat model of spinal cord injury.

Sources:

  • A dual-drug sequential delivery hydrogel for programmatic microglia/macrophage polarization and function recovery in spinal cord injury. Materials Today Bio, 2025;35:102365.
  • NewsRx. Hunan University Reports Findings in Spinal Cord Injury (A dual-drug sequential delivery hydrogel for programmatic microglia/macrophage polarization and function recovery in spinal cord injury). Immunotherapy Weekly. October 29, 2025; p 1728.

Read more